Grunnleggende statistikk
| CIK | 926844 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to China Botanic Pharmaceutical Inc
SEC Filings (Chronological Order)
På denne siden finner du en fullstendig, kronologisk liste over SEC-arkiveringer, med unntak av eierskaps-arkiveringer som vi leverer andre steder.
| August 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report: August 25, 2025 (Date of earliest event reported) FUSS BRANDS CORP. (Exact name of registrant as specified in its charter) Nevada 001-34808 87-1343424 (State of Incorporation) Commission File Number (IRS EIN) 80 Broad |
|
| June 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2025 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-34808 FUSS BRAND |
|
| March 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2025 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-34808 FUSS BRA |
|
| February 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended October 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NO. 001-34808 FUSS BRANDS CORP. (Exact name of |
|
| January 28, 2025 |
NT 10-K 1 fussbrandsnt10-k.htm NT 10-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 Notification of Late Filing (Check One): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form N-SAR For Period Ended: October 31, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q ☐ Transition Repo |
|
| September 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-34808 FUSS BRANDS |
|
| June 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-34808 FUSS BRAND |
|
| June 13, 2024 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 Notification of Late Filing (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form N-SAR For Period Ended: April 30, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q ☐ Transition Report on Form N-SAR For the Transition Perio |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report: May 8, 2024 (Date of earliest event reported) FUSS BRANDS CORP (Exact name of registrant as specified in its charter) Nevada 001-34808 87-1343424 (State of Incorporation) Commission File Number (IRS EIN) 80 Broad Stre |
|
| March 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-34808 FUSS BRA |
|
| February 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended October 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NO. 001-34808 FUSS BRANDS CORP. (Exact name of |
|
| January 29, 2024 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 Notification of Late Filing (Check One): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form N-SAR For Period Ended: October 31, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q ☐ Transition Report on Form N-SAR For the Transition Per |
|
| January 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 10, 2024 Fuss Brands Corp. (Exact Name of Registrant as Specified in its Charter) Nevada 001-34808 88-1273503 (State of incorporation) (Commission File Number) (IRS Employer I |
|
| January 11, 2024 |
RESOLUTION OF THE SHAREHOLDERS OF Fuss Brands Corp. January 10, 2024 Exhibit 99.1 RESOLUTION OF THE SHAREHOLDERS OF Fuss Brands Corp. DATED January 10, 2024 IN ATTENDANCE: Daniel Hirsch, Cheskel Meisels, representing 50.28% of Voting Rights We, being all the shareholders of Fuss Brands Corp. (the ‘Board’), a Corporation organized and existing under the laws of the State of Nevada under Entity Number C6679-1988 (the “Company”), hereby consent to the adoption of the |
|
| September 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-34808 FUSS BRANDS |
|
| June 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-34808 FUSS BRAND |
|
| March 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-34808 FUSS BRA |
|
| March 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 1, 2023 Fuss Brands Corp. (Exact Name of Registrant as Specified in its Charter) Nevada 001-34808 88-1273503 (State of incorporation) (Commission File Number) (IRS Employer Iden |
|
| March 2, 2023 |
Buying agency and sourcing services agreement, dated March 1, 2023. Exhibit 10.1 BUYING AGENCY AND SOURCING SERVICES AGREEMENT THIS BUYING AGENCY AND SOURCING SERVICES AGREEMENT (this “Agreement”) is entered into and made effective this 1st day of March, 2023 (the “Effective Date”) by and between Fuss Brands Corp., a Nevada corporation, located at 80 Broad Street, New York, New York 10004, U.S.A., a (hereinafter referred to as “Principal” or “Party”), and Inter Mu |
|
| January 27, 2023 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 26, 2023 Fuss Brands Corp. (Exact Name of Registrant as Specified in its Charter) Nevada 001-34808 88-1273503 (State of incorporation) (Commission File Number) (IRS Employer I |
|
| January 27, 2023 |
Purchase Order, dated January 26, 2023. Exhibit 10.1 |
|
| January 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended October 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NO. 001-34808 FUSS BRANDS CORP. (Exact name of |
|
| January 4, 2023 |
Employment Agreement, dated November 30, 2022. Exhibit 10.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this ?Agreement?) is dated as of November 30, 2022, by and between Fuss Brands Corp., a Nevada corporation (the ?Company?), and Issamar Ginzberg (the ?Executive?). WHEREAS, the Company wishes to employ the Executive as Chief Executive Officer of the Company and the Executive wishes to work as Chief Executive Officer of the Company; and W |
|
| January 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 30, 2022 Fuss Brands Corp. (Exact Name of Registrant as Specified in its Charter) Nevada 001-34808 87-1343424 (State of incorporation) (Commission File Number) (IRS Employe |
|
| December 5, 2022 |
Employment Agreement, dated November 30, 2022. Exhibit 10.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this ?Agreement?) is dated as of November 30, 2022, by and between Fuss Brands Corp., a Nevada corporation (the ?Company?), and Issamar Ginzberg (the ?Executive?). WHEREAS, the Company wishes to employ the Executive as Chief Executive Officer of the Company and the Executive wishes to work as Chief Executive Officer of the Company; and W |
|
| December 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 30, 2022 Fuss Brands Corp. (Exact Name of Registrant as Specified in its Charter) Nevada 001-34808 87-1343424 (State of incorporation) (Commission File Number) (IRS Employer |
|
| November 1, 2022 |
Anyvention Worldwide Irrevocable License Agreement, dated October 30, 2022. Exhibit 10.1 2 3 4 5 6 7 8 9 10 11 |
|
| November 1, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): October 30, 2022 Fuss Brands Corp. (Exact Name of Registrant as Specified in its Charter) Nevada 001-34808 88-1273503 (State of incorporation) (Commission File Number) (IRS Employer I |
|
| September 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ??QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2022 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-34808 FUSS BRANDS |
|
| August 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 13, 2022 Fuss Brands Corp. (Exact Name of Registrant as Specified in its Charter) Nevada 001-34808 87-1343424 (State of incorporation) (Commission File Number) (IRS Employer Iden |
|
| August 26, 2022 |
Certificate of Change, filed with the Secretary of State of the State of Nevada on July 13, 2022. Exhibit 3.2 |
|
| August 26, 2022 |
Certificate of Amendment, filed with the Secretary of State of the State of Nevada on July 14, 2022. Exhibit 3.1 |
|
| June 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2022 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-34808 CHINA BOTA |
|
| March 28, 2022 |
10-K/A 1 chinabotanic10ka2.htm 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A2 ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended October 31, 2013 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NO. 00 |
|
| February 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended October 31, 2013 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NO. 001-34808 CHINA BOTANIC PHARMACEUTICAL IN |
|
| February 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2022 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-34808 CHINA BO |
|
| December 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended October 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NO. 001-34808 CHINA BOTANIC PHARMACEUTICAL INC. |
|
| November 23, 2021 |
10-Q 1 chinabotanic410q.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2013 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34808 CH |
|
| November 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2013 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34808 CHINA BOTANIC PHARMACEUTICAL INC. (E |
|
| November 23, 2021 |
10-K 1 chinabotanic10k.htm 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended October 31, 2013 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NO. 001-34808 C |
|
| October 29, 2021 |
OMB APPROVAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: 3235-0167 Expires: July 31, 2024 Estimated average burden hours per response 1.50 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT O |
|
| September 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2021 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-34808 CHINA BOTAN |
|
| September 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: July 31, 2021 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form 10-Q ? Transition Report on Fo |
|
| August 25, 2021 |
8-K 1 chinabotanic8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 24, 2021 China Botanic Pharmaceutical Inc. (Exact Name of Registrant as Specified in its Charter) Nevada 001-34808 88-1273503 (State of incorporati |
|
| August 25, 2021 |
Exhibit 99.1 STOCK PURCHASE AGREEMENT THIS STOCK PURCHASE AGREEMENT, effective as of the August 23, 2021 (the ?Effective Date?) by and between Custodian Ventures LLC, a Wyoming limited liability company (?Seller?) and Issamar Ginzberg (?Buyer?). WHEREAS, Seller owns 1,000,000 shares of Series A-1 Preferred Stock, par value $.001 per share, (collectively, the ?Shares?) of China Botanic Pharmaceutic |
|
| August 25, 2021 |
DIRECTORS RESOLUTIONS OF CHINA BOTANIC PHARMACEUTICAL INC. (the “Company”) Exhibit 99.2 DIRECTORS RESOLUTIONS OF CHINA BOTANIC PHARMACEUTICAL INC. (the ?Company?) WHEREAS: A. David Lazar has consented to step down as Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary and as a Member of the Board of Directors of the Company. B. Issamar Ginzberg has consented to act as the new President, CEO, CFO, Treasurer, Secretary, and Chairman of the Board of Direc |
|
| August 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ? ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended October 31, 2012 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34808 CHINA BOTANIC PHARMACEUTICAL INC. (Exact |
|
| August 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2013 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34808 CHINA BOTANIC PHARMACEUTICAL INC. |
|
| July 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended October 31, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NO. 001-34808 CHINA BOTANIC PHARMACEUTICAL INC. |
|
| July 14, 2021 |
10-Q 1 chinabotanicphar042110q.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2021 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Com |
|
| July 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2021 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-34808 CHINA BO |
|
| February 17, 2021 |
Exhibit 99.1 |
|
| February 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 4, 2021 China Botanic Pharmaceutical, Inc. |
|
| June 20, 2013 |
AMERICAN STOCK EXCHANGE LLC NYSE MKT LLC DETERMINATION AND NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934 Attachment to Form 25 June 20, 2013 Pursuant to Section 12(d) of the Securities Exchange Act of 1934 and Rule 12d2-2(b) promulgated thereunder, NYSE MKT LLC (the “Exchange”), has determined to strike from listing and registration on the Exchange the following: China Botanic Pharmaceutical Inc. |
|
| June 6, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): (June 5, 2013) China Botanic Pharmaceutical Inc. (Exact name of registrant as specified in its charter) Nevada (State or Other Jurisdiction of Incorporation) 001-34808 (Commission Fil |
|
| June 6, 2013 |
CHINA BOTANIC PHARMACEUTICAL INC. ANNOUNCES WITHDRAWAL OF REQUEST FOR HEARING EXHIBIT 99.1 CHINA BOTANIC PHARMACEUTICAL INC. ANNOUNCES WITHDRAWAL OF REQUEST FOR HEARING Harbin, China –June 6, 2013 –China Botanic Pharmaceutical Inc. (AMEX: CBP) (formerly Renhuang Pharmaceuticals, Inc.) ("China Botanic" or the "Company"), a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines (“TCM”) in China, announced today tha |
|
| May 7, 2013 |
CHINA BOTANIC PHARMACEUTICAL INC. ANNOUNCES RECEIPT OF DELISTING NOTICE EXHIBIT 99.1 CHINA BOTANIC PHARMACEUTICAL INC. ANNOUNCES RECEIPT OF DELISTING NOTICE Harbin, China –May 7, 2013 –China Botanic Pharmaceutical Inc. (AMEX: CBP) (formerly Renhuang Pharmaceuticals, Inc.) ("China Botanic" or the "Company"), a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines (“TCM”) in China, announced today that on Ma |
|
| May 7, 2013 |
8-K 1 form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): (May 2, 2013) China Botanic Pharmaceutical Inc. (Exact name of registrant as specified in its charter) Nevada (State or Other Jurisdiction of Incorporation) 001-3480 |
|
| April 9, 2013 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant 8-K 1 form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): (April 3, 2013) China Botanic Pharmaceutical Inc. (Exact name of registrant as specified in its charter) Nevada (State or Other Jurisdiction of Incorporation) 001-34 |
|
| April 9, 2013 |
Established 1926 Landmark Square 111 West Ocean Blvd, 22nd Fl. Long Beach, CA 90801 (562) 435-1191 Von Karman Towers 18201 Von Karman Ave, Ste 1060 Irvine, CA 92612 (949) 271-2600 Figueroa at Wilshire 601 South Figueroa Street, Ste 4950 Los Angeles, CA 90017 www.windes.com April 3, 2013 U.S. Securities and Exchange Commission 100 F Street, NE Washington, DC 20549-6010 Dear Ladies and Gentlemen: We |
|
| April 2, 2013 |
EXHIBIT 99.1 CHINA BOTANIC PHARMACEUTICAL INC. ANNOUNCES RECEIPT OF NOTICE OF FAILURE TO SATISFY CONTINUED LISTING LETTER Harbin, China –April 2, 2013 –China Botanic Pharmaceutical Inc. (AMEX: CBP) (formerly Renhuang Pharmaceuticals, Inc.) ("China Botanic" or the "Company"), a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines (“TCM |
|
| April 2, 2013 |
8-K 1 form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): (March 27, 2013) China Botanic Pharmaceutical Inc. (Exact name of registrant as specified in its charter) Nevada (State or Other Jurisdiction of Incorporation) 001-3 |
|
| March 18, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB APPROVAL OMB Number: 3235-0058 Expires: August 31, 2015 Estimated average burden hours per response . . . . . . . 2.50 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001-34808 CUSIP NUMBER 16890Y104 (Check one): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: |
|
| February 5, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): (January 31, 2013) China Botanic Pharmaceutical Inc. (Exact name of registrant as specified in its charter) Nevada (State or Other Jurisdiction of Incorporation) 001-34808 (Commission |
|
| February 5, 2013 |
EXHIBIT 99.1 CHINA BOTANIC PHARMACEUTICAL INC. ANNOUNCES RECEIPT OF NOTICE OF FAILURE TO SATISFY CONTINUED LISTING LETTER Harbin, China –February 5, 2013 –China Botanic Pharmaceutical Inc. (AMEX: CBP) (formerly Renhuang Pharmaceuticals, Inc.) ("China Botanic" or the "Company"), a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines (“ |
|
| January 30, 2013 |
NT 10-K 1 form12b-25.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB APPROVAL OMB Number: 3235-0058 Expires: August 31, 2015 Estimated average burden hours per response . . . . . . . 2.50 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001-34808 CUSIP NUMBER 16890Y104 (Check one): x Form 10-K ¨ Form 20-F ¨ Form 11-K ¨ Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ For |
|
| January 23, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): (January 18, 2013) China Botanic Pharmaceutical Inc. (Exact name of registrant as specified in its charter) Nevada (State or Other Jurisdiction of Incorporation) 001-34808 (Commission |
|
| January 23, 2013 |
CHINA BOTANIC PHARMACEUTICAL INC. INDEPENDENT DIRECTOR AGREEMENT CHINA BOTANIC PHARMACEUTICAL INC. INDEPENDENT DIRECTOR AGREEMENT This Independent Director Agreement (the "Agreement") is made and entered into as of January 18, 2013, by and between China Botanic Pharmaceutical Inc., a Nevada company (the "Company"), and Jack Zhao, an individual (the "Director"). WHEREAS, the Company desires to engage the Director, and the Director desires to serve, as a non-empl |
|
| January 15, 2013 |
CHINA BOTANIC PHARMACEUTICAL INC. ANNOUNCES RECEIPT OF WARNING LETTER EXHIBIT 99.1 CHINA BOTANIC PHARMACEUTICAL INC. ANNOUNCES RECEIPT OF WARNING LETTER Harbin, China –January 15, 2013 –China Botanic Pharmaceutical Inc. (AMEX: CBP) (formerly Renhuang Pharmaceuticals, Inc.) ("China Botanic" or the "Company"), a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines (“TCM”) in China, announced today that it |
|
| January 15, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): (January 10, 2013) China Botanic Pharmaceutical Inc. (Exact name of registrant as specified in its charter) Nevada (State or Other Jurisdiction of Incorporation) 001-34808 (Commission |
|
| December 28, 2012 |
Dear Chairman Mr. Li Shaoming and CBP Board, EXHIBIT 17.1 Dear Chairman Mr. Li Shaoming and CBP Board, Due to the fact that the Company failed to renew the D&O insurance policy, the liability risks of public companies make it impossible for me to continue to serve on the Board and as the audit committee chairman of China Botanic Pharmaceuticals, Inc.(CBP). I hereby resign the position as the independent director and audit committee chairman |
|
| December 28, 2012 |
8-K 1 form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): (December 24, 2012) China Botanic Pharmaceutical Inc. (Exact name of registrant as specified in its charter) Nevada (State or Other Jurisdiction of Incorporation) 00 |
|
| September 20, 2012 |
Quarterly Report - FORM 10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) (Mark One) x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2012 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34808 CHINA |
|
| September 19, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2012 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34808 CHINA BOTANIC PHARMACEUTICAL INC. (E |
|
| September 14, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB APPROVAL OMB Number: 3235-0058 Expires: August 31, 2015 Estimated average burden hours per response . . . . . . . 2.50 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001-34808 CUSIP NUMBER (Check one): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: July 31, |
|
| June 19, 2012 |
Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2012 ¨ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34808 CHINA BOTANIC PHARMACEUTICAL INC. ( |
|
| June 14, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB APPROVAL OMB Number: 3235-0058 Expires: June 30, 2012 Estimated average burden hours per response . . . . . . . 2.50 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001-34808 CUSIP NUMBER (Check one): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: April 30, 2 |
|
| April 12, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 9, 2012 China Botanic Pharmaceutical Inc. (Exact name of registrant as specified in its charter) Nevada (State or Other Jurisdiction of Incorporation) 001-34808 (Commission File |
|
| April 12, 2012 |
China Botanic Announces Results of Annual General Meeting China Botanic Announces Results of Annual General Meeting HARBIN, China, April 10, 2012 /PRNewswire-Asia/ - China Botanic Pharmaceutical Inc. |
|
| March 19, 2012 |
China Botanic Reports First Quarter Fiscal 2012 Results Company Contact: China Botanic Pharmaceutical Inc. Ms. Portia Tan, IR ContactMr. David Dong Email: [email protected]: [email protected] Tel: 86-451-8260-2162 China Botanic Reports First Quarter Fiscal 2012 Results HARBIN, China, March 19, 2012 - China Botanic Pharmaceutical Inc. (NYSE AMEX: CBP) ("China Botanic" or the "Company"), a developer, manufacturer and distributor of botanical products |
|
| March 19, 2012 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2012 China Botanic Pharmaceutical Inc. (Exact name of registrant as specified in its charter) Nevada (State or Other Jurisdiction of Incorporation) 001-348 |
|
| March 16, 2012 |
Financial Statements and Exhibits, Other Events - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2012 China Botanic Pharmaceutical Inc. (Exact name of registrant as specified in its charter) Nevada (State or Other Jurisdiction of Incorporation) 001-34808 (Commission Fil |
|
| March 16, 2012 |
CHINA BOTANIC PHARMACEUTICAL INC. INDEPENDENT DIRECTOR AGREEMENT CHINA BOTANIC PHARMACEUTICAL INC. INDEPENDENT DIRECTOR AGREEMENT This Independent Director Agreement (the “Agreement”) is made and entered into as of October 15, 2011, by and between China Botanic Pharmaceutical Inc., a Nevada company (the “Company”), and Zack Zibing Pan , an individual (the “Director”). WHEREAS, the Company desires to engage the Director, and the Director desires to serve, as a n |
|
| March 16, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2012 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34808 CHINA BOTANIC PHARMACEUTICAL INC. |
|
| March 16, 2012 |
China Botanic Schedules Conference Call to Discuss Fiscal Year 2012 First Quarter Results Exhibit 99.1 Company Contact: CCG Investor Relations: China Botanic Pharmaceutical Inc. Mr. Mark Collinson, Partner Ms. Portia Tan, IR Contact Phone: +1-310-954-1343 (Los Angeles) Tel: 86-451-8260-2162 Email: [email protected] Email: [email protected] Website: www.ccgirasia.com Mr. Crocker Coulson, President Phone: +1-646-213-1915 (New York) Email: [email protected] For Immediate Rele |
|
| February 29, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant S Filed by a party other than the Registrant £ Check the appropriate box: £ Preliminary Proxy Statement £ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| February 1, 2012 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): (January 30, 2012) China Botanic Pharmaceutical Inc. (Exact name of registrant as specified in its charter) Nevada (State or Other Jurisdiction of Incorporation) 001-34808 (Commission |
|
| February 1, 2012 |
China Botanic Reports Fourth Quarter and Fiscal Year 2011 Results Company Contact: CCG Investor Relations: China Botanic Pharmaceutical Inc. Mr. Mark Collinson, Partner Ms. Portia Tan, IR Contact Phone: +1-310-954-1343 (Los Angeles) Tel: 86-451-8260-2162 Email: [email protected] Email: [email protected] Website: www.ccgirasia.com Mr. Crocker Coulson, President Phone: +1-646-213-1915 (New York) Email: [email protected] China Botanic Reports Fourth Qu |
|
| January 30, 2012 |
Translated from Chinese The Exclusive Licensing Agreement for Harbin Renhuang Pharmaceutical Co. |
|
| January 30, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended October 31, 2011 TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34808 CHINA BOTANIC PHARMACEUTICAL INC. (Exact name |
|
| January 10, 2012 |
Amended and Restated Bylaws(2) AMENDED AND RESTATED BYLAWS OF CHINA BOTANIC PHARMACEUTICAL INC. a Nevada corporation (as amended and restated, except to Section 2 of Article II, as of January 6, 2012) ARTICLE I: OFFICES Section 1. Registered Office and Registered Agent. The registered office of China Botanic Pharmaceutical Inc. (the “corporation”) in Nevada shall be located at 2215-B Renaissance Drive, Las Vegas, NV 89119 and t |
|
| January 10, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2012 China Botanic Pharmaceutical Inc. (Exact name of registrant as specified in its charter) Nevada (State or Other Jurisdiction of Incorporation) 001-34808 (Commission Fi |
|
| November 22, 2011 |
CHINA BOTANIC PHARMACEUTICAL INC. The 11th Floor, Changjiang International Building, No. 28, Changjiang Road, Nangang District, Harbin, Heilongjiang Province, P.R. China 150090 November 22, 2011 VIA EDGAR Securities and Exchange Commission Division of Corporate Finance 100 F Street, N.E. Washington, D.C. 20549 Re: China Botanic Pharmaceutical Inc. Form RW ? Withdrawal of Registration Statement on |
|
| October 18, 2011 |
8-K 1 v2374418k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 15, 2011 China Botanic Pharmaceutical Inc. (Exact name of registrant as specified in its charter) Nevada (State or Other Jurisdiction of Incorpora |
|
| October 18, 2011 |
China Botanic Appoints Zack Zibing Pan as an Independent Director and Chairman of its Audit Committee Press Release Source: China Botanic Pharmaceutical Inc. |
|
| October 18, 2011 |
China Botanic Announces Results of Annual General Meeting China Botanic Announces Results of Annual General Meeting HARBIN, China, Oct. 17, 2011 /PRNewswire-Asia/ - China Botanic Pharmaceutical Inc. (NYSE AMEX: CBP) ("China Botanic" or the "Company"), a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines ("TCM") in China, today announced the results of its annual general meeting of stockhol |
|
| October 13, 2011 |
China Botanic Announces Annual General Meeting of Stockholders China Botanic Announces Annual General Meeting of Stockholders Press Release Source: China Botanic Pharmaceutical Inc. |
|
| October 13, 2011 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 13, 2011 China Botanic Pharmaceutical Inc. (Exact name of registrant as specified in its charter) Nevada (State or Other Jurisdiction of Incorporation) 001-34808 (Commission F |
|
| September 15, 2011 |
DEF 14A 1 v234533def14a.htm DEFINITIVE PROXY STATEMENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a party other than the Registrant o Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confiden |
|
| September 14, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q 10-Q 1 v23467010q.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2011 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34808 CHIN |
|
| June 14, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q 10-Q 1 v22569210q.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2011 ¨ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34808 CHINA BOTANIC |
|
| March 18, 2011 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 v2152308k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 14, 2011 CHINA BOTANIC PHARMACEUTICAL INC. (Exact name of Registrant as Specified in its Charter) Nevada 0-24512 88-1273503 (State or Other Jurisdiction of I |
|
| March 18, 2011 |
China Botanic Pharmaceutical Expects to Receive a Tax Exemption in 2011 Company Contact: China Botanic Pharmaceutical Inc. Ms. Portia Tan, IR Contact Tel: 86-451-8260-2162 Email: [email protected] CCG Investor Relations: Mr. Mark Collinson, Partner Phone: +1-310-954-1343 (Los Angeles) Email: [email protected] Website: www.ccgirasia.com Mr. Crocker Coulson, President Phone: +1-646-213-1915 (New York) Email: [email protected] For Immediate Release China Bot |
|
| March 17, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2011 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34808 CHINA BOTANIC PHARMACEUTICAL INC. |
|
| March 17, 2011 |
EX-99.1 2 v215054ex99-1.htm Company Contact: CCG Investor Relations: China Botanic Pharmaceutical Inc. Mr. Mark Collinson, Partner Ms. Portia Tan, IR Contact Phone: +1-310-954-1343 (Los Angeles) Tel: 86-451-8260-2162 Email: [email protected] Email: [email protected] Website: www.ccgirasia.com Mr. Crocker Coulson, President Phone: +1-646-213-1915 (New York) Email: [email protected] For |
|
| March 17, 2011 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 17, 2011 CHINA BOTANIC PHARMACEUTICAL INC. (Exact name of Registrant as Specified in its Charter) Nevada 0-24512 88-1273503 (State or Other Jurisdiction of Incorporation) (Commi |
|
| March 10, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K/A (Amendment No. 1) x ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended October 31, 2010 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34808 CHINA BOTANIC PHARMAC |
|
| February 9, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 3, 2011 China Botanic Pharmaceutical Inc. (Exact name of registrant as specified in its charter) Nevada 001-34808 88-1273503 (State or Other Jurisdiction of Incorporation) (C |
|
| January 25, 2011 |
Results of Operations and Financial Condition, Financial Statements and Exhibits 8-K 1 v2089308k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 25, 2011 CHINA BOTANIC PHARMACEUTICAL INC. (Exact name of Registrant as Specified in its Charter) Nevada 0-24512 88-1273503 (State or Other Jurisd |
|
| January 25, 2011 |
Company Contact: CCG Investor Relations: China Botanic Pharmaceutical Inc. Mr. Mark Collinson, Partner Ms. Portia Tan, IR Contact Phone: +1-310-954-1343 (Los Angeles) Tel: 86-451-8260-2162 Email: [email protected] Email: [email protected] Website: www.ccgirasia.com Mr. Crocker Coulson, President Phone: +1-646-213-1915 (New York) Email: [email protected] For Immediate Release China Bot |
|
| January 24, 2011 | ||
| January 24, 2011 |
Employment Agreements with Weiqiu Dong(4) EXECUTIVE EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the ?Agreement?) is entered into as of December 14, 2010 by and between China Botanical Pharmaceutical Inc. |
|
| January 24, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K 10-K 1 v20854110k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K x ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended October 31, 2010 ¨ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34808 CHINA BOTANIC PHARM |
|
| January 18, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* CHINA BOTANIC PHARMACEUTICAL INC. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 16890Y104 (CUSIP Number) Li Shaoming 11th Floor, Changjiang International Building, No. 28, Changjiang Road, Nangang District, Harbin, Heilong |
|
| December 22, 2010 |
Financial Statements and Exhibits 8-K 1 v2063068k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 16, 2010 CHINA BOTANIC PHARMACEUTICAL INC. (Exact name of Registrant as Specified in its Charter) Nevada 0-24512 88-1273503 (State or Other Jurisdiction o |
|
| December 22, 2010 |
China Botanic Appoints David Dong as New Chief Financial Officer EX-99.1 2 v206306ex99-1.htm Company Contact: CCG Investor Relations: China Botanic Pharmaceutical Inc. Mr. Mark Collinson, Partner Ms. Portia Tan, IR Contact Phone: +1-310-954-1343 (Los Angeles) Tel: 86-451-8260-2162 Email: [email protected] Email: [email protected] Website: www.ccgirasia.com Mr. Crocker Coulson, President ePhone: +1-646-213-1915 (New York) Email: [email protected] Fo |
|
| December 6, 2010 |
As Filed with the Securities and Exchange Commission on December ____, 2010 As Filed with the Securities and Exchange Commission on December , 2010 Registration No. |
|
| December 2, 2010 |
Renhuang Pharmaceuticals Announces Name Change to China Botanic Pharmaceutical Inc. Company Contact: CCG Investor Relations: China Botanic Pharmaceutical Inc. Mr. Mark Collinson, Partner Ms. Portia Tan, IR Contact Phone: +1-310-954-1343 (Los Angeles) Tel: 86-451-8260-2162 Email: [email protected] Email: [email protected] Website: www.ccgirasia.com Mr. Crocker Coulson, President Phone: +1-646-213-1915 (New York) Email: [email protected] For Immediate Release Renhuang |
|
| December 2, 2010 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 29, 2010 CHINA BOTANIC PHARMACEUTICAL INC. (Exact name of Registrant as Specified in its Charter) Nevada 0-24512 88-1273503 (State or Other Jurisdiction of Incorporation) (Co |
|
| October 27, 2010 |
DEF 14C 1 v200130def14c.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14C (Rule 14c-101) SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: o Preliminary Information Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) x Definitive Info |
|
| October 15, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14C (Rule 14c-101) SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: [X] Preliminary Information Statement Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) [ ] Definitive Information Statement RENHUANG PHARMACEUTICALS, INC. |
|
| September 21, 2010 |
8-K 1 v1970558k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 20, 2010 RENHUANG PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in its Charter) Nevada 0-24512 88-1273503 (State or Other Jurisdiction of |
|
| September 21, 2010 |
Renhuang Reports Third Quarter 2010 Results Company Contact: CCG Investor Relations: Renhuang Pharmaceuticals, Inc. Mr. Mark Collinson, Partner Ms. Portia Tan, IR Contact Phone: +1-310-954-1343 (Los Angeles) Tel: 86-451-8260-2162 Email: [email protected] Email: [email protected] Website: www.ccgirasia.com Mr. Crocker Coulson, President Phone: +1-646-213-1915 (New York) Email: [email protected] For Immediate Release Renhuang Rep |
|
| September 17, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2010 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34808 RENHUANG PHARMACEUTICALS, INC. (Exac |
|
| September 15, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB APPROVAL OMB Number: 3235-0058 Expires: May 31, 2012 Estimated average burden hours per response . . . . . . . 2.50 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001-34808 CUSIP NUMBER (Check one): ? Form 10-K ? Form 20-F ? Form 11-K x Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: July 31, 201 |
|
| August 30, 2010 |
Renhuang Announces Appointment of Interim CFO EX-99.1 2 v195577ex99-1.htm Company Contact: CCG Investor Relations: Renhuang Pharmaceuticals, Inc. Mr. Mark Collinson, Partner Ms. Portia Tan, IR Contact Phone: +1-310-954-1343 (Los Angeles) Tel: 86-451-8260-2162 Email: [email protected] Email: [email protected] Website: www.ccgirasia.com Mr. Crocker Coulson, President Phone: +1-646-213-1915 (New York) Email: [email protected] For Im |
|
| August 30, 2010 |
8-K/A 1 v1955778-ka.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 20, 2010 RENHUANG PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in its Charter) Nevada 0-24512 88-1273503 (State or Other Jurisdiction |
|
| August 26, 2010 |
Renhuang Announces Appointment of Interim CFO EX-99.1 2 v195222ex99-1.htm Company Contact: CCG Investor Relations: Renhuang Pharmaceuticals, Inc. Mr. Mark Collinson, Partner Ms. Portia Tan, IR Contact Phone: +1-310-954-1343 (Los Angeles) Tel: 86-451-8260-2162 Email: [email protected] Email: [email protected] Website: www.ccgirasia.com Mr. Crocker Coulson, President Phone: +1-646-213-1915 (New York) Email: [email protected] For Im |
|
| August 26, 2010 |
8-K 1 v1952228k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 20, 2010 RENHUANG PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in its Charter) Nevada 0-24512 88-1273503 (State or Other Jurisdiction of Inc |
|
| August 9, 2010 |
Renhuang Announces Resignation of Chief Financial Officer Company Contact: CCG Investor Relations: Renhuang Pharmaceuticals, Inc. Mr. Mark Collinson, Partner Ms. Portia Tan, IR Contact Phone: +1-310-954-1343 (Los Angeles) Tel: 86-451-8260-2162 Email: [email protected] Email: [email protected] Website: www.ccgirasia.com Mr. Crocker Coulson, President Phone: +1-646-213-1915 (New York) Email: [email protected] For Immediate Release Renhuang Ann |
|
| August 9, 2010 |
8-K 1 v1929518k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 3, 2010 RENHUANG PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in its Charter) Nevada 0-24512 88-1273503 (State or Other Jurisdiction of Inco |
|
| July 14, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 8, 2010 RENHUANG PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in its Charter) Nevada 0-24512 84-1273503 (State or Other Jurisdiction of Incorporation) (Commission |
|
| July 14, 2010 |
EX-10.6 2 v190572ex10-6.htm The Acquisition Agreement of Acanthopanax（Siberian Ginseng） Resources PARTY A: Hongxing Forestry Bureau PARTY B: Harbin Renhuang Pharmaceuticals, Inc. For the purpose of the strategy “The ecology can establish the forestry zone and the industry can flourish the forestry zone”, the parties is based on the technical and capital advantage of Renhuang and the acanthopanax w |
|
| July 14, 2010 |
Renhuang Signs Exclusive Purchase Agreement for Siberian Ginseng EX-99.1 3 v190572ex99-1.htm Company Contact: CCG Investor Relations: Renhuang Pharmaceuticals, Inc. Mr. Mark Collinson, Partner Ms. Portia Tan, IR Contact Phone: +1-310-954-1343 (Los Angeles) Tel: 86-451-8260-2162 Email: [email protected] Email: [email protected] Website: www.ccgirasia.com Mr. Crocker Coulson, President Phone: +1-646-213-1915 (New York) Email: [email protected] For Im |
|
| July 2, 2010 |
Renhuang Pharmaceuticals Receives Approval to list on the NYSE Amex Company Contact: CCG Investor Relations: Renhuang Pharmaceuticals, Inc. Mr. Mark Collinson, Partner Ms. Portia Tan, IR Contact Phone: +1-310-954-1343 (Los Angeles) Tel: 86-451-8260-2162 Email: [email protected] Email: [email protected] Website: www.ccgirasia.com Mr. Crocker Coulson, President Phone: +1-646-213-1915 (New York) Email: [email protected] For Immediate Release Renhuang Pha |
|
| July 2, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Renhuang Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada 88-1273503 (State of incorporation or organization) (I.R.S. Employer Identification No.) No. 281, Taipin |
|
| July 2, 2010 |
Financial Statements and Exhibits, Other Events 8-K 1 v1898088k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 1, 2010 RENHUANG PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in its Charter) Nevada 0-24512 88-1273503 (State or Other Jurisdiction of Incorp |
|
| June 9, 2010 |
EX-99.1 2 v187843ex99-1.htm FINAL Company Contact: CCG Investor Relations: Renhuang Pharmaceuticals, Inc. Ms. Lei Huang, Account Manager Ms. Portia Tan, IR Contact Phone: +1-646-833-3417 (New York) Tel: 86-451-5392-5461 Email: [email protected] Email: [email protected] Website: www.ccgirasia.com Mr. Crocker Coulson, President Phone: +1-646-213-1915 (New York) Email: [email protected] For I |
|
| June 9, 2010 |
8-K 1 v1878438k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 7, 2010 RENHUANG PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in its Charter) Nevada 0-24512 88-1273503 (State or Other Jurisdiction of Incorp |
|
| June 9, 2010 |
Conference Call Transcript 2QF10 Results Renhuang Pharmaceuticals, Inc June 8th, 2010 Operator: Hi. |
|
| June 7, 2010 |
EX-10.6 2 v187388ex10-6.htm Property Sale and Purchase Contract The Seller: The Projects Department, Building11, Hongxiangmingyuan of Heilongjiang Yongtai Company (“Party A”) The Buyer: Harbin Renhuang Pharmaceuticals, Inc. (“Party B”) Business License No.:230100400006209 NOW, after friendly negotiations and in consideration of the Property and the mutual covenants contained herein, the Parties h |
|
| June 7, 2010 |
Independent Director Agreement with Mr. Changxiong Sun, dated April 19, 2010(9) RENHUANG PHARMACEUTICALS INC. INDEPENDENT DIRECTOR AGREEMENT 仁皇药业公司 独立董事协议 This Director Agreement (the “Agreement”) is made and entered into as of April 19th 2010 , by and between Renhuang Pharmaceuticals Inc., a Nevada company (the “Company”), and Changxiong Sun, an individual (the “Director”). 仁皇药业公司，一家内华达（“公司”）和孙长雄 个人（“董事” ）于 2010 年 4 月19日签署本董事协议（“协议”）。 I. SERVICES 服务 1.1 Board of Directors. D |
|
| June 7, 2010 |
Independent Director Agreement with Mr. Bingchun Wu, dated April 19, 2010(9) RENHUANG PHARMACEUTICALS INC. INDEPENDENT DIRECTOR AGREEMENT 仁皇药业公司 独立董事协议 This Director Agreement (the “Agreement”) is made and entered into as of April 19th 2010 , by and between Renhuang Pharmaceuticals Inc., a Nevada company (the “Company”), and Bingchun Wu, an individual (the “Director”). 仁皇药业公司，一家内华达（“公司”）和吴秉纯 个人（“董事”）于 2010 年 4 月19日签署本董事协议（“协议”）。 I. SERVICES 服务 1.1 Board of Directors. Direc |
|
| June 7, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION 10-Q 1 v18738810q.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2010 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-24512 RENHUANG PHAR |
|
| June 7, 2010 |
Independent Director Agreement with Mr. Xiaoheng (Sean) Shao, dated April 13, 2010(9) EX-10.7 3 v187388ex10-7.htm RENHUANG PHARMACEUTICALS INC. INDEPENDENT DIRECTOR AGREEMENT 仁皇药业公司 独立董事协议 This Director Agreement (the “Agreement”) is made and entered into as of April 13,2010, by and between Renhuang Pharmaceuticals Inc., a Nevada company (the “Company”), and Sean.Shao , an individual (the “Director”). 仁皇药业公司，一家内华达(“公司”)和邵孝恒 个人(“董事”)于 2010 年 4 月13 日签署本董事协议(“协议”)。 I. SERVICES 服务 1.1 |
|
| April 27, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 27, 2010 RENHUANG PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in its Charter) Nevada 0-24512 88-1273503 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| April 20, 2010 |
8-K 1 v1816648k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 20, 2010 RENHUANG PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in its Charter) Nevada 0-24512 88-1273503 (State or Other Jurisdiction of Inco |
|
| April 15, 2010 |
8-K 1 v1811878k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 13, 2010 RENHUANG PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in its Charter) Nevada 0-24512 88-1273503 (State or Other Jurisdiction of Inco |
|
| March 17, 2010 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2010 Renhuang Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) O-24512 (Commission File Num |
|
| March 17, 2010 |
Renhuang Announces First Quarter 2010 Results Company Contact: CCG Investor Relations: Renhuang Pharmaceuticals, Inc. Ms. Lei Huang, Account Manager Ms. Portia Tan, IR Contact Phone: +1-646-833-3417 (New York) Tel: 86-451-5392-5461 Email: [email protected] Email: [email protected] Website: www.ccgirasia.com Mr. Crocker Coulson, President Phone: +1-646-213-1915 (New York) Email: [email protected] For Immediate Release Renhuang Announce |
|
| March 16, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2010 ¨ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-24512 RENHUANG PHARMACEUTICALS, INC. (E |
|
| March 4, 2010 |
EX-99.2 4 v176307ex99-2.htm |
|
| March 4, 2010 |
Renhuang Announces Fiscal Year 2010 Guidance Company Contact: Renhuang Pharmaceuticals, Inc. Ms. Portia Tan, IR Contact Tel: 86-451-5392-5461 Email: [email protected] CCG Investor Relations: Ms. Lei Huang, Account Manager Phone: +1-646-833-3417 (New York) Email: [email protected] Website: www.ccgirasia.com Mr. Crocker Coulson, President Phone: +1-646-213-1915 (New York) Email: [email protected] For Immediate Release Renhuang Announce |
|
| March 4, 2010 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 v1763078k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2010 Renhuang Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) O-24512 ( |
|
| March 1, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K/A Amendment No. 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K/A Amendment No. 3 x ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended October 31, 2008 OR o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 0-24512 RENHUANG PHARMACEUTIC |
|
| February 9, 2010 |
Renhuang Reports Record Fiscal 2009 Results; Resumes Compliance With SEC Filing Requirements Renhuang Reports Record Fiscal 2009 Results; Resumes Compliance With SEC Filing Requirements HARBIN, China, Feb. |
|
| February 9, 2010 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 9, 2010 (February 8, 2010) Renhuang Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) O-24512 |
|
| February 4, 2010 |
Daniel B. Eng Direct Dial: (916) 930-2551 E-mail: [email protected] February 4, 2010 Via Edgar and U.S. Mail Jim B. Rosenberg Senior Assistant Chief Accountant United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 Re: Renhuang Pharmaceutical, Inc. Amendment No. 2 to Form 10-K for the Fiscal Year Ended October 31, 2008; SEC Fil |
|
| February 4, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K/A Amendment No. 2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K/A Amendment No. 2 x ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended October 31, 2008 OR o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 0-24512 RENHUANG PHARMACEUTIC |
|
| February 1, 2010 |
8-K/A 1 v1728008ka.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 1, 2010 (January 13, 2010) Renhuang Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada (State or ot |
|
| February 1, 2010 |
January 29, 2010 Securities Exchange Commission 450 Fifth Street, NW Washington, DC 20549 Re: Renhuang Pharmaceuticals, Inc. |
|
| January 29, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K x ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended October 31, 2009 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-24512 RENHUANG PHARMACEUTICALS, INC. (Exact nam |
|
| January 29, 2010 |
EX-10.3 2 v172311ex10-3.htm EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (“Agreement”), is dated as of January 13, 2010, by and between Renhuang Pharmaceuticals, Inc., a Nevada corporation (the “Company”), and Yan Yi Chen (the “Executive”). WHEREAS, the Company desires to employ the Executive, and the Executive desires to accept such employment, on the terms and conditions set forth herein, effe |
|
| January 29, 2010 |
English Translation CONTRACT OF THE TRANSFER OF THE PLANT The assignor (hereinafter referred to as Party A): Harbin Renhuang Pharmaceutical Stock Co, Ltd. |
|
| January 29, 2010 |
English translation of Purchase Agreement for Patents dated September 1, 2009(8) English Translation Patent Transfer Contract Party A (Transferor): Harbin Renhuang Pharmaceutical Stock Co, Ltd Yu Xi-Shui Wang You-Zhi Authorized Person: Wang Hong-Wei Party B (Transferee): Harbin Renhuang Pharmaceutical Co, Ltd Authorized Person: Li Shao-Ming The contract contains two transfers of patent rights: Item I Contract Object (I) Patent right A transferred in this Contract 1. |
|
| January 19, 2010 |
8-K 1 v1691538k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 19, 2010 (January 13, 2010) Renhuang Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of in |
|
| January 12, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q 10-Q 1 v17102610q.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2008 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number |
|
| January 12, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q 10-Q 1 v17102910q.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2008 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: |
|
| January 12, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q 10-Q 1 v17102410q.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2008 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file numb |
|
| January 7, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q 10-Q 1 v17079610q.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2009 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number |
|
| January 7, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q 10-Q 1 v17079710q.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2009 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file numb |
|
| December 8, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K Amendment No. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K Amendment No. 1 x ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended October 31, 2008 OR o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number O-24512 RENHUANG PHARMACEUTICAL |
|
| November 13, 2009 |
RENHUANG PHARMACEUTICALS, INC. No. 218, Taiping, Taiping District Harbin, Heilongjiang Province, P.R. China 150050 November 13, 2009 Sasha Singh Parikh Mail Stop 4720 Division of Corporation Finance Securities and Exchange Commission 100 F Street. N.E. Washington, D.C. 20549-4720 Re: Renhuang Pharmaceuticals, Inc. (the ?Company?) Item 4.02 Form 8-K Filed October 1, 2009 File No. 0-24512 Dear Ms. P |
|
| November 13, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Amendment No. 1 Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2009 Renhuang Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) O-24512 ( |
|
| October 30, 2009 |
RENHUANG PHARMACEUTICALS, INC. No. 218, Taiping, Taiping District Harbin, Heilongjiang Province, P.R. China 150050 October 30, 2009 United States Securities and Exchange Commission Division of Corporate Finance 100 F Street, N.E., Mail Stop 4720 Washington D.C. 20549 United States of America Attention: Ms. Sasha Parikh Re: Renhuang Pharmaceuticals, Inc. Item 4.02 Form 8-K Filed October 1, 2009 Fil |
|
| October 26, 2009 |
CORRESP 1 filename1.htm RENHUANG PHARMACEUTICALS, INC. No. 218, Taiping, Taiping District Harbin, Heilongjiang Province, P.R. China 150050 October 26, 2009 United States Securities and Exchange Commission Division of Corporate Finance 100 F Street, N.E., Mail Stop 4720 Washington D.C. 20549 United States of America Attention: Mr. Jim B. Rosenberg Sent Via Edgar Re: Renhuang Pharmaceuticals, Inc. ( |
|
| October 15, 2009 |
CORRESP 1 filename1.htm RENHUANG PHARMACEUTICALS, INC. No. 218, Taiping, Taiping District Harbin, Heilongjiang Province, P.R. China 150050 October 15, 2009 United States Securities and Exchange Commission Division of Corporate Finance 100 F Street, N.E., Mail Stop 4720 Washington D.C. 20549 United States of America Attention: Mr. Jim B. Rosenberg and Kei Ino Re: Renhuang Pharmaceuticals, Inc. Form |
|
| October 1, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 1, 2009 Renhuang Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) O-24512 (Commission File Nu |
|
| September 21, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2009 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: O-24512 RENHUANG PHAR |
|
| September 21, 2009 |
EX-10.1 2 v160852ex10-1.htm LOAN CONVERSION AGREEMENT This Loan Conversion Agreement (this “Agreement”) is dated May 15, 2009, among Renhuang Pharmaceuticals, Inc., a Nevada Corporation, (the “Company”) and the investors listed and identified on the signature pages hereto (each an “Investor” and together, the “Investors”). WHEREAS, the Investors provided the Company with a loan in the aggregate am |
|
| September 9, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K x ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended October 31, 2008 OR o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number O-24512 RENHUANG PHARMACEUTICALS, INC. (Exact n |
|
| January 15, 2009 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant 8-K 1 v1371788k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 15, 2009 Renhuang Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) O-2451 |
|
| January 15, 2009 |
Schwartz Levitsky Feldman llp CHARTERED ACCOUNTANTS LICENSED PUBLIC ACCOUNTANTS TORONTO · MONTREAL January 14, 2009 Securities and Exchange Commission Washington, D. |
|
| January 6, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 22, 2008 Renhuang Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) O-24512 (Commission File |
|
| October 14, 2008 |
8-K 1 v1288408k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 28, 2008 Renhuang Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) O-24 |
|
| August 11, 2008 |
10-Q/A 1 v11973310qa.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q/A (Amendment No. 1) (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2007 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to |
|
| August 11, 2008 |
10-Q/A 1 v11973810qa.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q/A (Amendment No. 1) (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2007 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| July 30, 2008 |
EXHIBIT 99.2 RESTATEMENT FOR QUARTER ENDED APRIL 30, 2007 The Company has restated its previously issued consolidated financial statements for the quarter ended January 31, 2007 and for the quarter ended April 30, 2007. During the review for the quarter ended July 31, 2007, the Company discovered an accounting error occurring in the filed financial statements for the quarter ended January 31, 2007 |
|
| July 30, 2008 |
8-K/A 1 v1212628ka.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 First Amended Form 8-K/A Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2007 Renhuang Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of inc |
|
| July 30, 2008 |
EX-99.1 2 v121262ex99-1.htm EXHIBIT 99.1 RESTATEMENT FOR QUARTER ENDED JANUARY 31, 2007 The Company has restated its previously issued consolidated financial statements for the quarter ended January 31, 2007 and for the quarter ended April 30, 2007. During the review for the quarter ended July 31, 2007, the Company discovered an accounting error occurring in the filed financial statements for the |
|
| July 30, 2008 |
THE LEBRECHT GROUP A PROFESSIONAL LAW CORPORATION THE LEBRECHT GROUP A PROFESSIONAL LAW CORPORATION Brian A. Lebrecht, Esq. Edward H. Weaver, Esq.** Craig V. Butler, Esq. * Admitted only in California* Admitted only in Utah** July 28, 2008 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Mail Stop 6010 Attn: Keira Ino Re: Renhuang Pharmaceuticals, Inc. Item 4.02 Form 8-K Filed July 14 |
|
| July 14, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2007 Renhuang Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) O-24512 (Commission File Nu |
|
| May 29, 2008 | ||
| May 29, 2008 | ||
| May 29, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K x ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended October 31, 2007 OR o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number O-24512 RENHUANG PHARMACEUTICALS, INC. (Exact n |
|
| May 22, 2008 |
8-K 1 v1156578k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2008 Renhuang Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) O-24512 (C |
|
| September 19, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2007 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: O-24512 RENHUANG PHAR |
|
| September 14, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION SEC File No: O-24512 Washington, D. |
|
| June 14, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q 10-Q 1 v07846910q.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2007 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number |
|
| May 2, 2007 |
2007 Non-Qualified Company Stock Grant and Option Plan(5) RENHUANG PHARMACEUTICALS, INC. 2007 NON-QUALIFIED COMPANY STOCK GRANT AND OPTION PLAN 1. PURPOSE: This 2007 Non-Qualified Company Stock Grant and Option Plan (the “Plan”) is intended to serve as an incentive to and to encourage stock ownership by certain directors, officers, employees of and certain persons rendering service to Renhuang Pharmaceuticals, Inc., a Nevada corporation (the “Corporation |
|
| May 2, 2007 |
As filed with the Securities and Exchange Commission on May 1, 2007 As filed with the Securities and Exchange Commission on May 1, 2007 Registration No. |
|
| May 2, 2007 |
[FORM OF] RENHUANG PHARMACEUTICALS, INC. Stock Option Agreement Under 2007 Non-Qualified Company Stock Grant and Option Plan THIS STOCK OPTION AGREEMENT is entered into the day of , 20, between Renhuang Pharmaceuticals, Inc., a Nevada corporation (the ?Corporation? or ?Grantor?) and (the ?Grantee?), with respect to the following facts: Pursuant and subject to the Corporation?s 2007 Non-Qualified C |
|
| May 2, 2007 |
EX-4.3 4 v073340ex4-3.htm [FORM OF] RENHUANG PHARMACEUTICALS, INC. Common Stock Purchase Agreement Under 2007 Non-Qualified Company Stock Grant and Option Plan THIS AGREEMENT is dated as of , 20, between Renhuang Pharmaceuticals, Inc., a Nevada corporation (the “Company”), and (“Purchaser”). WITNESSETH: WHEREAS, pursuant to the terms of a Agreement dated , 20, by and between Purchaser and the Comp |
|
| April 20, 2007 |
8-K 1 v0721798k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 16, 2007 Renhuang Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) O-24512 |
|
| March 19, 2007 |
EX-10.7 2 v068876ex10-7.htm ASSET PURCHASE AGREEMENT ASSET PURCHASE AGREEMENT dated as of February 28, 2007 (this "Agreement") by and among Harbin Renhuang Pharmaceuticals Co, Ltd., (the "Buyer") a corporation incorporated in the Peoples Republic of China, “PRC”, and Zhongfa Industrial Group Yerui Pharmaceutical Co., Ltd., (the “Seller’) a corporation incorporated in the Peoples Republic of China, |
|
| March 19, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2007 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: O-24512 RENHUA |
|
| February 28, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 First Amended Form 10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 First Amended Form 10-Q/A (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2006 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: O-245 |
|
| February 28, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 First Amended Form 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 First Amended Form 10-K/A [X] ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended April 30, 2006 OR [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number O-24512 RENHUANG PHARMACEUTIC |
|
| February 28, 2007 | ||
| February 22, 2007 |
EX-10.6 7 v066627ex10-6.htm Loan Agreement Party A: Harbin Renhuang Pharmaceuticals Inc. Party B: Heilongjiang Yuejintiande Building and Installation Project Co.,Ltd Due to the demand of Party B in an important investment in Daqing city, and based on the friendly consultation of parties A and B, both parties have entered into the Loan Agreement as follows: 1. Due to the demand of Party B in Teachi |
|
| February 22, 2007 | ||
| February 22, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 First Amended Form 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 First Amended Form 10-K/A [ ] ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended OR [X] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from May 1, 2006 to October 31, 2006. Commission file number O-24512 RENHUANG |
|
| February 22, 2007 |
Subsidiaries of Renhuang Pharmaceuticals, Inc. Exhibit 21.1 Subsidiaries of Renhuang Pharmaceuticals, Inc. 1) Harbin Renhuang Pharmaceutical Company Ltd., a British Virgin Island company - 100% subsidiary of Renhuang Pharmaceutical, Inc. 2) Harbin Renhuang Pharmaceutical Co. Ltd., a Chinese company - 100% subsidiary of Harbin Renhuang Pharmaceutical Company, Ltd. |
|
| February 13, 2007 |
EX-10.6 10 v065547ex10-6.htm Loan Agreement Party A: Harbin Renhuang Pharmaceuticals Inc. Party B: Heilongjiang Yuejintiande Building and Installation Project Co.,Ltd Due to the demand of Party B in an important investment in Daqing city, and based on the friendly consultation of parties A and B, both parties have entered into the Loan Agreement as follows: 1. Due to the demand of Party B in Teach |
|
| February 13, 2007 |
Subsidiaries of Renhuang Pharmaceuticals, Inc. EX-21.1 11 v065547ex21-1.htm Exhibit 21.1 Subsidiaries of Renhuang Pharmaceuticals, Inc. 1) Harbin Renhuang Pharmaceutical Company Ltd., a British Virgin Island company - 100% subsidiary of Renhuang Pharmaceutical, Inc. 2) Harbin Renhuang Pharmaceutical Co. Ltd., a Chinese company - 100% subsidiary of Harbin Renhuang Pharmaceutical Company, Ltd. |
|
| February 13, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K o ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended OR x TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from May 1, 2006 to October 31, 2006. Commission file number O-24512 RENHUANG PHARMACEUTICALS, IN |
|
| February 13, 2007 |
Certificate of Amendment to Articles of Incorporation(3) EX-3.2 5 v065547ex3-2.htm |
|
| January 31, 2007 |
8-K 1 v0640448k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 25, 2007 Renhuang Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) O-2451 |
|
| December 8, 2006 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2006 Renhuang Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) O-24512 (Commission File N |
|
| December 8, 2006 |
[Rotenberg & Co., LLP Letterhead] December 5, 2006 EXHIBIT 16.1 [Rotenberg & Co., LLP Letterhead] December 5, 2006 Securities and Exchange Commission 450 Fifth Street, N.W. Washington, D.C. 20549 Ladies and Gentlemen: We were previously the independent registered public accounting firm for Renhuang Pharmaceuticals, Inc. (?the Company?) and, under the date of August 9, 2006, we reported on the financial statements of the Company as of and for the y |
|
| September 18, 2006 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-QSB Back to Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-QSB x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2006 OR o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Renhuang Pharmaceuticals, Inc. |
|
| September 11, 2006 |
HARBIN RENHUANG PHARMACEUTICAL STOCK CO., LTD (INCORPORATED IN THE PRC) FINANCIAL STATEMENTS APRIL 30, 2006 AND 2005 INDEX TO FINANCIAL STATEMENTS Balance Sheets as of April 30, 2006 (Unaudited) and October 31, 2005 F-2 - F-3 Statements of Income for the six months ended April 30, 2006 and 2005 (Unaudited) F-4 Statements of Cash Flows for the six months ended April 30, 2006 and 2005 (Unaudited) F- |
|
| September 11, 2006 |
EX-99.1 6 v052360ex99-1.htm HARBIN RENHUANG PHARMACEUTICAL STOCK CO., LTD (INCORPORATED IN THE PRC) FINANCIAL STATEMENTS OCTOBER 31, 2005 AND 2004 INDEX TO FINANCIAL STATEMENTS Independent Auditors' Report F-2 Balance Sheets as of October 31, 2005 and 2004 F-3 – F-4 Statements of Income for the years ended October 31, 2005 and 2004 F-5 Statements of Changes in Equity for the years ended October, 2 |
|
| September 11, 2006 |
8-K 1 v0523608k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 8, 2006 Renhuang Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada (State or Other Jurisdiction of Incorporation) 0-24512 |
|
| August 29, 2006 |
EX-10.1 2 v051705ex10-1.htm SHARE EXCHANGE AGREEMENT THIS SHARE EXCHANGE AGREEMENT, dated as of the 28th day of August, 2006 (the “Agreement”), by and among Renhuang Pharmaceuticals, Inc., a Nevada corporation (the “Company”); the BVI Shareholders, as listed at the end of this Agreement, each a “Seller” and collectively the “Sellers”, Harbin Renhuang Pharmaceutical Company Limited, a corporation i |
|
| August 29, 2006 |
Entry into a Material Definitive Agreement 8-K 1 v0517058k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 29, 2006 Renhuang Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Nevada (State or Other Jurisdiction of Incorporation) 0-24512 8 |
|
| December 15, 2004 |
Anza 12b-25 10Q 10.31.04 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ? Form 10-K ? Form 20-F x Form 10-Q o Form N-SAR For Period Ended: October 31, 2004 ? Transition report on Form 10-K ? Transition report on Form 20-F ? Transition report on Form 11-K ? Transition report on Form 10-Q ? Transition report on Form N-SAR |
|
| September 14, 2004 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ? Form 10-K ? Form 20-F x Form 10-Q o Form N-SAR For Period Ended: July 31, 2004 ? Transition report on Form 10-K ? Transition report on Form 20-F ? Transition report on Form 11-K ? Transition report on Form 10-Q ? Transition report on Form N-SAR For the Transition Period En |
|
| August 24, 2004 |
Exhibit 16.01 August 24, 2004 Securities and Exchange Commission 450 Fifth Street, N. W. Washington, DC 20549 Commission File No. 0-24512 Ladies and Gentlemen: We have read Item 4.01 of Anza Capital, Inc. Form 8-K dated August 20, 2004, and are in agreement with the statements in Item 4.01 contained therein, as they relate to our firm. Very truly yours, /s/ Mc Kennon, Wilson & Morgan LLP |
|
| August 24, 2004 |
Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 20, 2004 Anza Capital, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) O-24512 (Commission File Number) 88-127 |
|
| August 16, 2004 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K [X] ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended April 30, 2004 OR [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number O-24512 Anza Capital, Inc. (Exact name of registrant as spe |
|
| July 29, 2004 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): x Form 10-K ? Form 20-F ? Form 10-Q o Form N-SAR For Period Ended: April 30, 2004 ? Transition report on Form 10-K ? Transition report on Form 20-F ? Transition report on Form 11-K ? Transition report on Form 10-Q ? Transition report on Form N-SAR For the Transition Period E |
|
| March 22, 2004 |
EX-10.2 3 amrestcertdes.htm AMENDED REST CERT DES SERIES A PFD AMENDED AND RESTATED CERTIFICATE OF DESIGNATION OF THE RIGHTS, PREFERENCES, PRIVILEGES AND RESTRICTIONS, WHICH HAVE NOT BEEN SET FORTH IN THE CERTIFICATE OF INCORPORATION OR IN ANY AMENDMENT THERETO, OF THE SERIES A PREFERRED STOCK OF AMERICAN RESIDENTIAL FUNDING, INC. The undersigned, Vincent Rinehart and Veneranda Toledo, do hereby c |
|
| March 22, 2004 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q 10-Q 1 anza10q31jan2004body.htm ANZA 10-Q 1.31.04 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2004 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| March 16, 2004 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ? Form 10-K ? Form 20-F x Form 10-Q o Form N-SAR For Period Ended: January 31, 2004 ? Transition report on Form 10-K ? Transition report on Form 20-F ? Transition report on Form 11-K ? Transition report on Form 10-Q ? Transition report on Form N-SAR For the Transition Period |
|
| December 23, 2003 |
MUTUAL RESCISSION OF SECURITIES EXCHANGE AGREEMENT EX-10.1 3 mutualrescissionagreement.htm MUTUAL RESCISSION OF EXCHANGE AGREEMENT MUTUAL RESCISSION OF SECURITIES EXCHANGE AGREEMENT This Mutual Rescission of Securities Exchange Agreement (the "Rescission Agreement") is entered into effective this 18th day of December, 2003 by and between Anza Capital, Inc., a Nevada corporation ("Anza"), American Residential Funding, Inc., a Nevada corporation ("A |
|
| December 23, 2003 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 18, 2003 Anza Capital, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) O-24512 (Commission File Number) 88-1273503 (I.R.S. |
|
| December 15, 2003 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Anza Capital 10-Q 10.31.03 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 31, 2003 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number O-24512 Anza Capital, Inc |
|
| September 16, 2003 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): [ ] Form 10-KSB [ ] Form 20-F [ X ] Form 10-QSB [ ] Form N-SAR For Period Ended : July 31, 2003 [ ] Transition report on Form 10-K [ ] Transition report on Form 20-F [ ] Transition report on Form 11-K [ ] Transition report on Form 10-Q Transition report on Form N-SAR For the |
|
| September 16, 2003 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2003 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number O-24512 Anza Capital, Inc. (Exact name of registrant as |
|
| August 15, 2003 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 First Amended Form 10-KSB/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 First Amended Form 10-KSB/A [X] ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended April 30, 2003 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number O-24512 Anza Capital, Inc. (Exact name of re |
|
| August 13, 2003 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-KSB SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-KSB [X] ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended April 30, 2003 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number O-24512 Anza Capital, Inc. (Exact name of registrant as spec |
|
| August 4, 2003 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2003 Anza Capital, Inc. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation) O-24512 (Commission File Number) 88-1273503 (I.R.S. Emp |
|
| August 4, 2003 |
EX-9.2 6 proxyreanzacommonstock.htm PROXY RE ANZA COMMON STOCK IRREVOCABLE PROXY The undersigned (i) a stockholder of American Residential Funding, Inc., a Nevada corporation (“AMRES”), and (ii) a warrantholder of Anza Capital, Inc., a Nevada corporation (“Anza”), hereby irrevocably (to the full extent permitted by law) appoints Vincent Rinehart and any individual designated by said individual, th |
|
| August 4, 2003 |
SECURITIES EXCHANGE AGREEMENT by and between ANZA CAPITAL, INC., a Nevada corporation, AMERICAN RESIDENTIAL FUNDING, INC., a Nevada corporation, and SUTTER HOLDING COMPANY, INC., a Delaware corporation SECURITIES EXCHANGE AGREEMENT This Securities Exchange Agreement (the ?Agreement?) is entered into effective this 18th day of July, 2003 by and between Anza Capital, Inc., a Nevada corporation (?Anz |
|
| August 4, 2003 |
EX-9.1 5 proxyresuttercommonstock.htm PROXY RE SUTTER COMMON STOCK IRREVOCABLE PROXY The undersigned stockholder of Sutter Holdings Company, Inc., a Delaware corporation (“Sutter”), hereby irrevocably (to the full extent permitted by law) appoints Robert E. Dixon and any individual designated by said individual, the attorney and proxy of the undersigned with full power of substitution and resubsti |
|
| August 4, 2003 |
CERTIFICATE OF DESIGNATION OF THE RIGHTS, PREFERENCES, PRIVILEGES AND RESTRICTIONS, WHICH HAVE NOT BEEN SET FORTH IN THE CERTIFICATE OF INCORPORATION OR IN ANY AMENDMENT THERETO, OF THE SERIES A PREFERRED STOCK OF AMERICAN RESIDENTIAL FUNDING, INC. |
|
| August 4, 2003 |
EX-4.1 3 anzawarrantsutter.htm ANZA WARRANT TO SUTTER HOLDING CO. THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (“THE ACT”), OR THE SECURITIES LAWS OF ANY STATE, AND MAY NOT BE OFFERED, SOLD, TRANSFERRED, PLEDGED, HYPOTHECATED OR OTHERWISE DISPOSED OF EXCEPT PURSUANT TO (i) AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT AND |
|
| July 29, 2003 |
NT 10-K 1 anza12b25body10ksb.htm ANZA 12B-25 FOR 10KSB 4.30.03 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): [X] Form 10-KSB [ ] Form 20-F [ ] Form 10-QSB [ ] Form N-SAR For Period Ended : April 30, 2003 [ ] Transition report on Form 10-K [ ] Transition report on Form 20-F [ ] Transition report on Form 11-K [ ] Transiti |
|
| April 22, 2003 |
THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED ("THE ACT"), OR THE SECURITIES LAWS OF ANY STATE, AND MAY NOT BE OFFERED, SOLD, TRANSFERRED, PLEDGED, HYPOTHECATED OR OTHERWISE DISPOSED OF EXCEPT PURSUANT TO (i) AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT AND ANY APPLICABLE STATE LAWS, (ii) TO THE EXTENT APPLICABLE, RULE 144 UNDER THE ACT (OR ANY SIMILAR RULE UNDER THE ACT RELATING TO THE DISPOSITION OF SECURITIES), OR (iii) AN OPINION OF COUNSEL, IF SUCH OPINION SHALL BE REASONABLY SATISFACTORY TO COUNSEL TO THE ISSUER, THAT AN EXEMPTION FROM REGISTRATION UNDER THE ACT AND APPLICABLE STATE LAW IS AVAILABLE. |
